We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma

MedXY Editorial Team•Nov 13, 2025•news
Gastric CancerimmunotherapyPD-1TIGIT

Highlights

• Dual TIGIT and PD‑1 blockade with domvanalimab and zimberelimab added to FOLFOX produced a confirmed objective response rate (ORR) of 59% in previously untreated HER2‑negative advanced gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma (n=41).

• Median progression‑free survival (PFS) was 12.9 months and median overall survival (OS) was 26.7 months in the study cohort; responses were higher among PD‑L1–positive tumors.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Clinical Outcomes and Prognostic Factors in Lung Metastases Following Gastrectomy for Gastric CancerThis review summarizes the clinical characteristics, disease course, and survival outcomes of lung metastases after gastrectomy in gastric cancer patients, highlighting prognostic factors and the role of pulmonary metastasectomy.Sep 7, 2026Targeting the CXCL9/CXCL10-CXCR3+ CD8+ T Cell Axis: Unraveling Anti-PD-1 Antibody-Associated Cardiotoxicity in Pressure Overload Heart FailureAnti-PD-1 antibody exacerbates pressure overload-induced heart failure by promoting CXCR3+ CD8+ T cell infiltration, which impairs cardiomyocyte mitochondrial function via granzyme B and perforin. This study identifies a novel immunopathogeSep 6, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Sep 6, 2026
Unveiling the Molecular Evolution from Primary Gastric Cancer to Peritoneal Metastases: Implications for Targeted Surgical OncologyThis study elucidates transcriptomic differences between primary gastric cancers and peritoneal metastases, revealing distinct tumor microenvironments and molecular pathways, highlighting potential targets for improved diagnosis and therapySep 5, 2026
Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple MyelomaMezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.Sep 3, 2026